Cisplatin (Platinol ®)
Efficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma
Lung Cancer 2025 May [Link] Ernest Nadal, Paloma Martín-Martorell, Jose Carlos Benítez, Maria Ángeles Sala, Susana Cedrés, Carlos Álvarez, Manuel Dómine, Elia Sais 8, Maria Saigí, Rafael López, Laia Vilà, Bartomeu Massutí, Rosario García-Campelo, Andres Mesas-Ruiz, Amelia Insa, Sílvia Plans-Marín, Sara Hijazo-Pechero, Cristina Muñoz-Pinedo, Jesús Brenes, Mariano Provencio Abstract Objectives: We aimed to evaluate the…
Read MorePD-L1 pfeRNAs as blood-based predictors of treatment response of unresectable malignant pleural mesothelioma patients administered Durvalumab with cisplatin and pemetrexed as first-line therapy
Non-Coding RNA Research 2025 February 21 [Link] Andrei Gurau, Suguru Yamauchi, Kaitlyn Ecoff, Kristen P Rodgers, James R Eshleman, Charles Conover Talbot Jr, Peng Huang, Joshua Choi, Patrick M Forde, Valsamo Anagnostou, Malcolm Brock, Yuping Mei Abstract Background: A new therapeutic avenue combining Durvalumab with cisplatin-pemetrexed (Durva-CP) has delivered a promising outcome for previously untreated…
Read MoremiRNA-503 inhibition exerts anticancer effects and reduces tumor growth in mesothelioma
Journal of Experimental & Clinical Cancer Research 2025 February 22 [Link] Miriam Piccioni, Francesco Di Meo, Anna Valentino, Virginia Campani, Maddalena Arigoni, Mirella Tanori, Mariateresa Mancuso, Rossana Cuciniello, Marco Tomasetti, Federica Monaco, Gaia Goteri, Enrico P Spugnini, Raffaele A Calogero, Giuseppe De Rosa, Gianfranco Peluso, Alfonso Baldi, Stefania Crispi Abstract Background: Malignant mesothelioma (MM) is…
Read MoreA Meta-Analysis of First-Line Treatments for Unresectable Pleural Mesothelioma: Indirect Comparisons from Reconstructed Individual Patient Data of Six Randomized Controlled Trials
Cancers 2025 February 3 [Link] Andrea Messori, Sabrina Trippoli, Eugenia Piragine, Sara Veneziano, Vincenzo Calderone Abstract Background: In unresectable pleural mesothelioma, pemetrexed+cisplatin as first line is considered the standard of care, but novel treatments have been recently proposed. Methods: Our objective was to compare, albeit indirectly, the results of randomized controlled trials on overall survival…
Read MoreThe impact of Charcot-Leyden Crystal protein on mesothelioma chemotherapy: targeting eosinophils for enhanced chemosensitivity
EBioMedicine 2024 November [Link] Mégane Willems, Malik Hamaidia, Alexis Fontaine, Mélanie Grégoire, Louise Halkin, Lea Vilanova Mañá, Roxane Terres, Majeed Jamakhani, Sophie Deshayes, Yves Brostaux, Vincent Heinen, Renaud Louis, Bernard Duysinx, Didier Jean, Eric Wasielewski, Arnaud Scherpereel, Christophe Blanquart, Luc Willems Abstract Background: In mesothelioma (MPM), clinical evidence indicates that the absolute eosinophil count negatively…
Read MoreComparison of First-Line Chemotherapeutics and Validation of the EORTC Prognostic Index in Malignant Pleural Mesothelioma: Retrospective Single-Centre Experience
Journal of the College of Physicians and Surgeons 2024 August [Link] Yasin Sezgin, Ogur Karhan, Serdar Ileri, Senar Ebinc, Sezai Tunc, Zuhat Urakci Abstract Objective: To evaluate the efficiency of pemetrexed cisplatin in comparison with gemcitabine cisplatin and to validate the EORTC (European Organisation for Research and Treatment of Cancer) prognostic score in combination chemotherapy…
Read MoreChemotherapy increases CDA expression and sensitizes malignant pleural mesothelioma cells to capecitabine treatment
Scientific Reports 2024 August 6 [Link] Darya Karatkevich, Tereza Losmanova, Philipp Zens, Haibin Deng, Christelle Dubey, Tuo Zhang, Corsin Casty, Yanyun Gao, Christina Neppl, Sabina Berezowska, Wenxiang Wang, Ren-Wang Peng, Ralph Alexander Schmid, Patrick Dorn, Thomas Michael Marti Abstract The combination of cisplatin and pemetrexed remains the gold standard chemotherapy for malignant pleural mesothelioma (MPM),…
Read MoreContemporary management of mesothelioma
Breathe 2024 July 16 [Link] Mark D J Neilly, Jennifer Pearson, Akari Win Thu, Carolyn MacRae, Kevin G Blyth Abstract Pleural mesothelioma (PM) is an aggressive asbestos-associated thoracic malignancy with a median survival of 12-18 months. Due to continued asbestos use in many nations, global incidence is rising. Causes due to non-occupational, environmental exposure are…
Read MoreIntegration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study
PloS One 2024 July 15 [Link] Jolien Van den Bossche, Maxime De Laere, Koen Deschepper, Paul Germonpré, Yvan Valcke, Jan Lamont, Barbara Stein, Kirsten Van Camp, Charlotte Germonpré, Griet Nijs, Ella Roelant, Sébastien Anguille, Eva Lion, Zwi Berneman Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer with a very poor prognosis. Recently, immune checkpoint…
Read MorePharmacological inhibition of CDK4/6 impairs diffuse pleural mesothelioma 3D spheroid growth and reduces viability of cisplatin-resistant cells
Frontiers in Oncology 2024 July 1 [Link] Aurora Costa, Iris Maria Forte, Francesca Pentimalli, Carmelina Antonella Iannuzzi, Luigi Alfano, Francesca Capone, Rosa Camerlingo, Alessandra Calabrese, Claudia von Arx, Reyes Benot Dominguez, Massimiliano Quintiliani, Michelino De Laurentiis, Andrea Morrione, Antonio Giordano Abstract Introduction: Diffuse pleural mesothelioma (DPM) of the pleura is a highly aggressive and treatment-resistant…
Read More